Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.

Tytuł :
Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.
Autorzy :
Kim KA; Department of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, 126-1, 5-Ga, Anam-dong, Seongbuk-Gu, Seoul, 136-705, South Korea.
Park IB; Department of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, 126-1, 5-Ga, Anam-dong, Seongbuk-Gu, Seoul, 136-705, South Korea.
Park JY; Department of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, 126-1, 5-Ga, Anam-dong, Seongbuk-Gu, Seoul, 136-705, South Korea. .
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2018 Oct; Vol. 74 (10), pp. 1281-1289. Date of Electronic Publication: 2018 Jun 13.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: Berlin, New York, Springer.
MeSH Terms :
Tamsulosin*/administration & dosage
Tamsulosin*/blood
Tamsulosin*/pharmacokinetics
Cytochrome P-450 CYP2D6/*genetics
Cytochrome P-450 CYP3A/*genetics
Hemodynamics/*drug effects
Prostatic Hyperplasia/*drug therapy
Adrenergic alpha-1 Receptor Antagonists/administration & dosage ; Adrenergic alpha-1 Receptor Antagonists/blood ; Adrenergic alpha-1 Receptor Antagonists/pharmacokinetics ; Adult ; Biological Availability ; Blood Pressure/drug effects ; Humans ; Male ; Pharmacogenetics ; Polymorphism, Genetic ; Prostatic Hyperplasia/genetics
References :
Pharmacogenetics. 2001 Dec;11(9):773-9. (PMID: 11740341)
J Pharm Biomed Anal. 2007 Jan 17;43(2):606-12. (PMID: 16920322)
Drug Metab Dispos. 2003 Jan;31(1):53-9. (PMID: 12485953)
Clin Ther. 2006 Nov;28(11):1837-47. (PMID: 17213004)
Clin Chim Acta. 2014 Jan 20;428:77-81. (PMID: 24262967)
Clin Pharmacol Ther. 2014 Sep;96(3):340-8. (PMID: 24926778)
Clin Pharmacol Ther. 2008 Sep;84(3):347-61. (PMID: 18231117)
Drug Metabol Drug Interact. 2013;28(4):209-16. (PMID: 24088607)
J Clin Pharmacol. 2007 Jan;47(1):87-93. (PMID: 17192506)
BMJ. 2013 Nov 05;347:f6320. (PMID: 24192967)
Pharmacogenomics J. 2004;4(1):34-9. (PMID: 14647405)
Trends Pharmacol Sci. 1999 Aug;20(8):342-9. (PMID: 10431214)
Xenobiotica. 1996 Jun;26(6):637-45. (PMID: 8810034)
Rev Urol. 2009 Fall;11(Suppl 1):S1-8. (PMID: 20126606)
J Clin Pharmacol. 1996 Nov;36(11):1029-38. (PMID: 8973992)
Nat Genet. 2001 Apr;27(4):383-91. (PMID: 11279519)
Rev Urol. 2005;7 Suppl 4:S13-21. (PMID: 16986050)
Clin Ther. 2004 May;26(5):715-23. (PMID: 15220015)
J Clin Pharm Ther. 2009 Oct;34(5):569-74. (PMID: 19744012)
Expert Opin Drug Saf. 2014 Sep;13(9):1187-97. (PMID: 25073735)
Clin Pharmacol Ther. 2006 Jun;79(6):590-9. (PMID: 16765147)
Annu Rev Pharmacol Toxicol. 1997;37:269-96. (PMID: 9131254)
Br J Clin Pharmacol. 1998 Jan;45(1):49-55. (PMID: 9489594)
Clin Pharmacokinet. 2010 Mar;49(3):177-88. (PMID: 20170206)
Drug Metab Rev. 2007;39(4):699-721. (PMID: 18058330)
Genet Med. 2017 Jan;19(1):69-76. (PMID: 27388693)
Eur J Clin Pharmacol. 2008 Jun;64(6):589-97. (PMID: 18385991)
Br J Clin Pharmacol. 2011 Aug;72(2):247-56. (PMID: 21496064)
J Chromatogr B Biomed Sci Appl. 1997 Aug 1;695(2):317-27. (PMID: 9300868)
J Urol. 2004 Mar;171(3):1029-35. (PMID: 14767264)
Drugs. 2002;62(1):135-67. (PMID: 11790159)
Drug Metab Dispos. 2009 Jul;37(7):1464-70. (PMID: 19364831)
Xenobiotica. 1998 Oct;28(10):909-22. (PMID: 9849639)
J Clin Pharmacol. 2012 Dec;52(12):1934-8. (PMID: 22245658)
Contributed Indexing :
Keywords: CYP2D6; CYP3A5; Hemodynamics; Pharmacogenetics; Pharmacokinetics; Single-nucleotide polymorphism; Tamsulosin
Substance Nomenclature :
0 (Adrenergic alpha-1 Receptor Antagonists)
EC 1.14.14.1 (CYP3A5 protein, human)
EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
G3P28OML5I (Tamsulosin)
Entry Date(s) :
Date Created: 20180628 Date Completed: 20181219 Latest Revision: 20181219
Update Code :
20210914
DOI :
10.1007/s00228-018-2501-x
PMID :
29947950
Czasopismo naukowe
Purpose: Tamsulosin is one of the most potent drugs currently available to treat benign prostatic hyperplasia. Cytochrome P450 (CYP) 2D6 and CYP3A are the two major enzymes responsible for tamsulosin metabolism. The purpose of this study was to evaluate the effects of CYP2D6 and CYP3A5 genetic polymorphisms on the pharmacokinetics and hemodynamic effects of tamsulosin in humans.
Methods: Twenty-nine male subjects were enrolled and their CYP2D6 (*2,*4,*5,*10,*14,*21,*41, and *xN) and CYP3A5 (*5) genotypes were screened. Tamsulosin was administered daily for 6 days to assess its steady-state pharmacokinetics and hemodynamic effects according to CYP2D6 and CYP3A5 genotypes.
Results: CYP2D6 group 3 (with genotype *10/*10 or *5/*10) exhibited higher plasma levels than CYP2D6 group 1 (with genotype *1/*1,*1/*2,*1/*2xN, or *2/*10xN) or CYP2D6 group 2 (with genotype *1/*10,*1/*41, or *2/*5) (trough concentrations for groups 1, 2, and 3: 1.3, 1.8, and 3.8 ng/mL, respectively [P < 0.001]; peak concentrations for groups 1, 2, 3: 8.3, 10.0, and 13.8 ng/mL, respectively [P < 0.005]). Similarly, CYP2D6 genotypes influenced the hemodynamic effects of tamsulosin based on systolic and diastolic blood pressures. However, the CYP3A5*3 polymorphism did not affect tamsulosin plasma levels and its hemodynamic effects.
Conclusion: The CYP2D6 but not the CYP3A5 genetic polymorphisms affected the pharmacokinetics and the hemodynamic effects of tamsulosin.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies